We have located links that may give you full text access.
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Sub-analysis of a prospective, randomized, controlled study (PRIME-V study).
Journal of Diabetes Investigation 2020 July 5
INTRODUCTION: Recent randomized clinical trials have suggested that sodium-glucose co-transporter-2 (SGLT2) inhibitors may reduce cardiovascular events and heart failure and have renal protective effects. Despite these remarkable benefits, the effects of SGLT2 inhibitors on bone and muscle are unclear.
METHODS: A sub-analysis of a randomized controlled study was performed to evaluate the effects of the SGLT2 inhibitor, ipragliflozin, versus metformin on bone and muscle in Japanese patients with type 2 diabetes mellitus (baseline BMI ≥ 22 kg/m2 and HbA1c 7-10 %) who were already receiving sitagliptin. These patients were randomly administered ipragliflozin 50 mg or metformin 1000-1500 mg daily. The effects of these medications on the bone formation marker, bone alkali phosphatase (BAP); the bone resorption marker, tartrate-resistant acid phosphatase 5b (TRACP-5b); handgrip strength; abdominal cross-sectional muscle area; and bone density of the fourth lumbar vertebra were evaluated.
RESULTS: After 24 weeks of treatment, the changes in bone density of the fourth lumbar vertebra, handgrip strength, and abdominal cross-sectional muscle area were not significantly different between the two groups. However, TRACP-5b levels increased in patients treated with ipragliflozin compared to patients treated with metformin (median 11.94 % vs. -10.30 %, P < 0.0001), indicating that ipragliflozin can promote bone resorption.
CONCLUSIONS: There were no adverse effects on bone or muscle when sitagliptin was used in combination with either ipragliflozin or metformin. However, ipragliflozin combination increased the levels of TRACP-5b. A long-term study is needed to further understand the effects of this TRACP-5b increase caused by ipragliflozin.
CLINICAL TRIAL REGISTRATION: https://www.umin.ac.jp/ctr/ (UMIN-ID: UMIN 000015170).
METHODS: A sub-analysis of a randomized controlled study was performed to evaluate the effects of the SGLT2 inhibitor, ipragliflozin, versus metformin on bone and muscle in Japanese patients with type 2 diabetes mellitus (baseline BMI ≥ 22 kg/m2 and HbA1c 7-10 %) who were already receiving sitagliptin. These patients were randomly administered ipragliflozin 50 mg or metformin 1000-1500 mg daily. The effects of these medications on the bone formation marker, bone alkali phosphatase (BAP); the bone resorption marker, tartrate-resistant acid phosphatase 5b (TRACP-5b); handgrip strength; abdominal cross-sectional muscle area; and bone density of the fourth lumbar vertebra were evaluated.
RESULTS: After 24 weeks of treatment, the changes in bone density of the fourth lumbar vertebra, handgrip strength, and abdominal cross-sectional muscle area were not significantly different between the two groups. However, TRACP-5b levels increased in patients treated with ipragliflozin compared to patients treated with metformin (median 11.94 % vs. -10.30 %, P < 0.0001), indicating that ipragliflozin can promote bone resorption.
CONCLUSIONS: There were no adverse effects on bone or muscle when sitagliptin was used in combination with either ipragliflozin or metformin. However, ipragliflozin combination increased the levels of TRACP-5b. A long-term study is needed to further understand the effects of this TRACP-5b increase caused by ipragliflozin.
CLINICAL TRIAL REGISTRATION: https://www.umin.ac.jp/ctr/ (UMIN-ID: UMIN 000015170).
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app